MAXCYTE, INC.
MXCTNasdaq
$1.24
↓ -8.1%Jul 17 close · end-of-day
Price
1Y↓ -41.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$132.5M
Enterprise Value
$25.7M
P/E
—
P/S
4.1
P/B
0.8
EV/EBITDA
—
PEG
—
FCF Yield
-22.1%
Dividend Yield
—
Revenue (TTM)
$32.3M
Net Income (TTM)
-$39.1M
Free Cash Flow (TTM)
-$29.4M
Gross Margin
80.5%
Operating Margin
-141.8%
Net Margin
-121.2%
ROE
-23.3%
ROIC
-59.3%
Debt / Equity
—
Net Cash
$106.9M
Return 1Y
-42.3%
Company profile
MaxCyte, Inc. engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection. The company was incorporated in 1998 and is headquartered in Gaithersburg, Maryland.
- CEO
- Douglas A. Doerfler
- Sector
- Services
- Industry
- Business Services
- Employees
- 80
- Headquarters
- Maryland
- Website
- maxcyte.com
Management & directors
- Ahuja ParmeetChief Financial Officer
- Masoud MaherPresident and CEO
- Swirsky Douglas JCHIEF FINANCIAL OFFICER
Roles derived from SEC Form 4 filings.
Earnings
MXCT Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$9.7M↓ -7.1%
Diluted EPS-$0.04↓ -60.0%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $26.2M | $33.9M | $44.3M | $41.3M | $38.6M | $33.0M |
| Gross profit | $23.4M | $30.2M | $39.2M | $36.5M | $31.5M | $26.8M |
| Operating income | -$11.1M | -$18.2M | -$27.4M | -$48.3M | -$51.2M | -$51.9M |
| Net income | -$11.8M | -$19.1M | -$23.6M | -$37.9M | -$41.1M | -$44.6M |
| Diluted EPS | -$0.17 | -$0.21 | -$0.23 | -$0.37 | -$0.39 | -$0.42 |
| Operating cash flow | -$8.8M | -$10.7M | -$14.8M | -$21.7M | -$27.6M | -$34.4M |
| Free cash flow | -$10.9M | -$14.5M | -$33.3M | -$25.4M | -$29.3M | -$36.2M |
| Gross margin | 89.4% | 89.2% | 88.5% | 88.5% | 81.6% | 81.2% |
| Operating margin | -42.3% | -53.7% | -61.8% | -117.0% | -132.5% | -157.1% |
| Net margin | -45.2% | -56.3% | -53.3% | -91.8% | -106.3% | -135.1% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $10.4M | $8.2M | $8.7M | $10.4M | $8.5M | $6.8M | $7.3M | $9.7M |
| Gross profit | $8.9M | $6.2M | $6.4M | $8.9M | $7.0M | $5.2M | $5.7M | $8.1M |
| Operating income | -$12.0M | -$14.1M | -$12.9M | -$12.3M | -$14.2M | -$14.1M | -$11.2M | -$6.2M |
| Net income | -$9.4M | -$11.6M | -$10.6M | -$10.3M | -$12.4M | -$12.4M | -$9.6M | -$4.8M |
| Diluted EPS | -$0.09 | -$0.11 | — | -$0.10 | -$0.12 | -$0.12 | -$0.08 | -$0.04 |
| Operating cash flow | -$4.8M | -$4.4M | -$7.8M | -$14.4M | -$9.9M | -$7.5M | -$2.7M | -$8.2M |
| Free cash flow | -$5.1M | -$4.8M | -$8.0M | -$15.1M | -$10.4M | -$7.8M | -$2.9M | -$8.2M |
| Gross margin | 85.7% | 76.4% | 73.8% | 85.6% | 82.1% | 76.6% | 77.9% | 83.7% |
| Operating margin | -114.8% | -172.1% | -148.4% | -118.3% | -167.2% | -207.2% | -153.8% | -64.1% |
| Net margin | -89.9% | -141.6% | -121.9% | -98.8% | -145.3% | -181.8% | -131.5% | -49.2% |
Company news
Jul 15, 2026
Jun 23, 2026
May 13, 2026
- 68d ago12 Health Care Stocks Moving In Wednesday's Intraday Sessionfinance.yahoo.com
- 68d agoHere’s Why MaxCyte (MXCT) is Becoming a High-Conviction Bet for Investorsfinance.yahoo.com
- 68d agoCisco, Alibaba And 3 Stocks To Watch Heading Into Wednesdayfinance.yahoo.com
- 68d agoMaxCyte Inc (MXCT) Q1 2026 Earnings Call Highlights: Revenue Meets Expectations Amid Core ...finance.yahoo.com
- 68d agoMaxCyte Q1 Earnings Call Highlightsmarketbeat.com
- 68d agoMaxCyte, Inc. Q1 2026 Earnings Call Summaryapp.moby.co
May 12, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-06-17 | Johnston John Joseph | Award | 30,421 | $0.00 | $0.00 | filing |
| 2026-06-17 | Hemrajani Rekha | Award | 30,421 | $0.00 | $0.00 | filing |
| 2026-06-17 | Erck Stanley C | Award | 30,421 | $0.00 | $0.00 | filing |
| 2026-06-17 | DOUGLAS RICHARD | Award | 30,421 | $0.00 | $0.00 | filing |
| 2026-06-17 | Collins Cynthia | Award | 30,421 | $0.00 | $0.00 | filing |
| 2026-06-17 | Brooke William W | Award | 30,421 | $0.00 | $0.00 | filing |
| 2026-06-17 | BALTHROP PATRICK J | Award | 30,421 | $0.00 | $0.00 | filing |
| 2026-06-17 | Al-Wakeel Yasir B. | Award | 30,421 | $0.00 | $0.00 | filing |
| 2026-04-15 | Ahuja Parmeet· Chief Financial Officer | Award | 187,500 | $0.00 | $0.00 | filing |
| 2026-03-27 | Masoud Maher· President and CEO | Award | 300,000 | $0.00 | $0.00 | filing |
| 2026-03-17 | Swirsky Douglas J· CHIEF FINANCIAL OFFICER | Sale | 10,142 | $0.82 | $8,265.73 | filing |
| 2025-08-13 | Erck Stanley C | Buy | 100,000 | $1.37 | $137,220.00 | filing |
| 2025-08-13 | DOUGLAS RICHARD | Buy | 80,000 | $1.39 | $111,040.00 | filing |
| 2025-08-13 | Masoud Maher· President and CEO | Buy | 75,000 | $1.37 | $102,915.00 | filing |
| 2025-08-13 | Swirsky Douglas J· CHIEF FINANCIAL OFFICER | Buy | 50,000 | $1.29 | $64,500.00 | filing |
| 2025-08-13 | Brooke William W | Buy | 50,000 | $1.29 | $64,500.00 | filing |
| 2025-06-25 | Hemrajani Rekha | Sale | 10,684 | $2.09 | $22,377.64 | filing |
| 2025-06-18 | Johnston John Joseph | Award | 29,210 | $0.00 | $0.00 | filing |
| 2025-06-18 | Hemrajani Rekha | Award | 29,210 | $0.00 | $0.00 | filing |
| 2025-06-18 | Erck Stanley C | Award | 29,210 | $0.00 | $0.00 | filing |
| 2025-06-18 | DOUGLAS RICHARD | Award | 29,210 | $0.00 | $0.00 | filing |
| 2025-06-18 | Collins Cynthia | Award | 29,210 | $0.00 | $0.00 | filing |
| 2025-06-18 | Brooke William W | Award | 29,210 | $0.00 | $0.00 | filing |
| 2025-06-18 | BALTHROP PATRICK J | Award | 29,210 | $0.00 | $0.00 | filing |
| 2025-06-18 | Al-Wakeel Yasir B. | Award | 29,210 | $0.00 | $0.00 | filing |
Latest 25 transactions.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.